

## Musculoskeletal Australia



MUSCULOSKELETAL  
AUSTRALIA

### Consumer input to the Pharmaceutical Benefits Advisory Committee (PBAC)

#### Musculoskeletal relevant drugs for consideration at the November 2021 PBAC Meeting

Below is a list of the musculoskeletal relevant drugs for consideration by the PBAC at their next meeting in November 2021. Consumer comments about any of these drugs must be received by the PBAC **by 5pm (AEST) on Wednesday 22 September 2021**.

If you wish to submit your comments to PBAC with the help of the MSK staff, please respond to the questions in the last column of the table below via email **by no later than 5pm (AEST) on Wednesday, 15 September 2021**. Please send your email responses to [info@msk.org.au](mailto:info@msk.org.au)

<b>Drug name</b>	<b>Musculoskeletal condition/s</b> (What is the drug used to treat?)	<b>Purpose of the submission</b> (Nature of the request by the sponsor or drug company)	<b>If you wish to make a comment about these requests via MSK, please respond to the following questions</b>
ADALIMUBAB (New PBS listing)	Severe active juvenile idiopathic arthritis; Severe active rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis	Alphapharm Pty Ltd is requesting the listing of the Adalimumab biosimilar under the same conditions as its reference biologic. The brand name is Hulio®	1) How does having any of the listed conditions affect your daily life? 2) What are the reasons why your current treatment isn't fully meeting your needs? 3) What do you think would be the benefits (or additional benefits) of having this drug available? 4) Are there any reasons why you think this request should not be approved?

Drug name	Musculoskeletal condition/s (What is the drug used to treat?)	Purpose of the submission (Nature of the request by the sponsor or drug company)	If you wish to make a comment about these requests via MSK, please respond to the following questions
ETANERCEPT (New PBS listing)	Rheumatoid arthritis; Ankylosing spondylitis; Psoriatic arthritis; Juvenile idiopathic arthritis	Alphapharm Pty Ltd is requesting the listing of the Etanercept biosimilar under the same conditions as its reference biologic, with exclusion of children and adolescents who weigh less than 62.5 kg. The brand name is Rymti®	1) How does having any of the listed conditions affect your daily life? 2) What are the reasons why your current treatment isn't fully meeting your needs? 3) What do you think would be the benefits of having the biosimilar available? 4) Are there any reasons why you think this request should not be approved?
IXEKIZUMAB (Change to PBS listing)	Non radiographic axial spondyloarthritis (nr-axSpA)	Eli Lilly Australia Pty Ltd is requesting a General Schedule Authority Required (Written) listing of this drug for the treatment of nr-axSpA, under the same circumstances as currently PBS listed biological disease-modifying anti-rheumatic agents for this indication.	1) How does having nr-axSpA affect your daily life? 2) What are the reasons why your current treatment isn't fully meeting your needs? 3) What do you think would be the benefits of having this drug available? 4) Are there any reasons why you think this request should not be approved?

Drug name	Musculoskeletal condition/s (What is the drug used to treat?)	Purpose of the submission (Nature of the request by the sponsor or drug company)	If you wish to make a comment about these requests via MSK, please respond to the following questions
PREGABALIN (New PBS listing)	Neuropathic pain	Upjohn Australia Pty Ltd is requesting a General Schedule Authority Required (STREAMLINED) listing of Pregabalin <b>tablets of varying doses</b> for the treatment of neuropathic pain in adults, where this condition does not respond to treatment with other drugs. The brand name is Lyrica®	<ol style="list-style-type: none"> <li>1) How does having neuropathic pain affect your daily life?</li> <li>2) What are the reasons why your current treatment isn't fully meeting your needs?</li> <li>3) What do you think would be the advantages of having this drug available?</li> <li>4) Are there any reasons why you think this request should not be approved?</li> </ol>
PREGABALIN (New PBS listing)	Neuropathic pain	AFT Pharmaceuticals (Au) Pty Ltd is requesting a General Schedule Authority Required (STREAMLINED) listing of Pregabalin <b>solution</b> under the same circumstances as the existing listings of pregabalin capsules.	<ol style="list-style-type: none"> <li>1) How does having neuropathic pain affect your daily life?</li> <li>2) What are the reasons why your current treatment isn't fully meeting your needs?</li> <li>3) What do you think would be the advantages of having this drug available as a solution?</li> <li>4) Are there any reasons why you think this request should not be approved?</li> </ol>

Drug name	Musculoskeletal condition/s (What is the drug used to treat?)	Purpose of the submission (Nature of the request by the sponsor or drug company)	If you wish to make a comment about these requests via MSK, please respond to the following questions
RITUXIMAB (New PBS listing)	Rheumatoid arthritis (RA)	Pfizer Australia Pty Ltd is requesting the listing of rituximab biosimilar under the same conditions as the currently listed rituximab. The brand name is Ruxience®	1) How does having RA affect your daily life? 2) What are the reasons why your current treatment isn't fully meeting your needs? 3) What do you think would be the advantages of having this drug available for IV infusion? 4) Are there any reasons why you think this request should not be approved?